Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2014

01-12-2014 | Hepatobiliary Tumors

CT-Guided High-Dose-Rate Brachytherapy of Liver Tumours Does Not Impair Hepatic Function and Shows High Overall Safety and Favourable Survival Rates

Authors: Georg Brinkhaus, MD, Johan Friso Lock, MD, Maciej Malinowski, MD, PhD, Timm Denecke, MD, PhD, Peter Neuhaus, MD, Bernd Hamm, MD, Bernhard Gebauer, MD, Martin Stockmann, MD, PhD

Published in: Annals of Surgical Oncology | Issue 13/2014

Login to get access

Abstract

Background or Purpose

Computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT) is an emerging therapeutic option for irresectable liver tumours. However, its potentially negative effect on liver function has not yet been investigated. The aim of this study was to evaluate CT-HDRBT for potential liver damage and functional impairment by means of quantitative liver function tests, patient safety, and survival.

Methods

Sixty-nine patients receiving hepatic CT-HDRBT were investigated in a prospective study. The liver function was determined before and after intervention, and 6 and 12 weeks later. The study visits included liver function assessment by conventional biochemical parameters, the liver function capacity test based on 13C-Methacetin (MA) kinetics in µg/kg/hr (LiMAx test), and the indocyanine green plasma disappearance rate test. Tumour progression was re-staged by magnetic resonance imaging (MRI) twice. The 2-year-survival was analysed.

Results

A significant alteration of biochemical liver parameters was observed for liver enzymes and bilirubin directly after intervention, all biochemical parameters had normalised at the 6-week follow-up. There were no changes in LiMAx test values after the intervention, showing no effect on metabolic liver function capacity. In approximately two-thirds of the patients, MRI re-staging revealed a significant tumour response, and no local tumour recurrence occurred. No patient developed a radiation-induced liver disease.

Conclusion

CT-HDRBT for local tumour treatment has little impact on total liver function capacity by high patient safety and encouraging survival rates. Thus, it should be an important option in treating patients without a surgical alternative, especially when liver function is impaired due to previous surgery or chronic liver disease.
Literature
1.
Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol. 2011;21:287–93.PubMedCrossRef
2.
Mohnike K, Wieners G, Schwartz F, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys. 2010;78:172–9.PubMedCrossRef
3.
Denecke T, Lopez Hanninen E. Brachytherapy of liver metastases. Recent Results Cancer Res. 2008;177:95–104.PubMedCrossRef
4.
Tselis N, Chatzikonstantinou G, Kolotas C, et al. Hypofractionated accelerated computed tomography-guided interstitial high-dose-rate brachytherapy for liver malignancies. Brachytherapy. 2012;11:507–14.PubMedCrossRef
5.
Tselis N, Chatzikonstantinou G, Kolotas C, et al. Computed tomography-guided interstitial high dose rate brachytherapy for central located liver tumours: a single institution study. Eur Radiol. 2013;23:2264–70.PubMedCrossRef
6.
Seidensticker M, Seidensticker R, Mohnike K, et al. Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiat Oncol. 2011;6:40.PubMedCentralPubMedCrossRef
7.
Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–21.PubMedCrossRef
8.
Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.PubMedCrossRef
9.
Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:10–9.CrossRef
10.
Stockmann M, Lock JF, Malinowski M, et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB. 2010;12:139–46.PubMedCentralPubMedCrossRef
11.
Rühl R, Lüdemann L, Czarnecka A, et. al. Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases. Radiat Oncol. 2010;5:44PubMedCentralPubMedCrossRef
12.
Ricke J, Wust P, Wieners G, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15:1279–86.PubMedCrossRef
13.
Wieners G, Pech M, Rudzinska M, et. al. CT-guided interstitial brachytherapy in the local treatment of extrahepatic, extrapulmonary secondary malignancies. Eur Radiol. 2006;16:2586–2593.PubMedCrossRef
14.
Ricke J, Mohnike K, Pech M, et. al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;78:479–485PubMedCrossRef
15.
Schnapauff D, Denecke T, Grieser C, et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2012;35:581–7.PubMedCrossRef
16.
Collettini F, Poellinger A, Schnapauff D, et al. CT-guided high-dose-rate brachytherapy of metachronous ovarian cancer metastasis to the liver: initial experience. Anticancer Res. 2011;31:2597–602.PubMed
17.
Ruhl R, Seidensticker M, Peters N, et al. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy. Dig Dis. 2009;27:189–99.PubMedCrossRef
18.
Stockmann M, Lock JF, Riecke B, et. al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009;250:119–25.PubMedCrossRef
19.
Stockmann M, Malinowski M, Lock JF, Seehofer D, Neuhaus P. Factors influencing the indocyanine green (ICG) test: additional impact of acute cholestasis. Hepatogastroenterology. 2009;56:734–8PubMed
20.
Lock J, Malinowski M, Seehofer D, et al. Function and volume recovery after partial hepatectomy: influence of preoperative liver function, residual liver volume, and obesity. Langenbecks Arch Surg. 2012;397:1297–304.PubMedCrossRef
21.
Ricke J, Wust P, Wieners G, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15(11):1279–86.PubMedCrossRef
22.
Wieners G, Mohnike K, Peters N, et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy—a phase II-study. Radiother Oncol. 2011;100:314–9.PubMedCrossRef
23.
Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:20–37.CrossRef
24.
Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 2009;45:1748–56.PubMedCrossRef
25.
Curley SA. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol. 2008;15:11–3.PubMedCentralPubMedCrossRef
Metadata
Title
CT-Guided High-Dose-Rate Brachytherapy of Liver Tumours Does Not Impair Hepatic Function and Shows High Overall Safety and Favourable Survival Rates
Authors
Georg Brinkhaus, MD
Johan Friso Lock, MD
Maciej Malinowski, MD, PhD
Timm Denecke, MD, PhD
Peter Neuhaus, MD
Bernd Hamm, MD
Bernhard Gebauer, MD
Martin Stockmann, MD, PhD
Publication date
01-12-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 13/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3835-y

Other articles of this Issue 13/2014

Annals of Surgical Oncology 13/2014 Go to the issue

Urologic Oncology

Factors Influencing the Length of Stay after Radical Cystectomy: Implications for Cancer Care and Perioperative Management

Bone and Soft Tissue Sarcomas

A Promise to Our Patients with Metastatic Bone Disease

Bone and Soft Tissue Sarcomas

Atypical Lipomatous Tumors: Should They be Treated Like Other Sarcoma or Not? Surgical Consideration from a Bi-Institutional Experience

Gastrointestinal Oncology

The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses

Urologic Oncology

A Novel Method for Intraoperative Sentinel Lymph Node Detection in Prostate Cancer Patients Using Superparamagnetic Iron Oxide Nanoparticles and a Handheld Magnetometer: The Initial Clinical Experience

Thoracic Oncology

Homozygous GNAS 393C-Allele Carriers with Locally Advanced Esophageal Cancer Fail to Benefit from Platinum-Based Preoperative Chemoradiotherapy